15.44

6.93% 1.00

After Hours: 16.43 0.99 +6.41%

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $15.44, with a volume of 2.16M. It is up +6.93% in the last 24 hours and down -2.22% over the past month. Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Previous Close:

$14.44

Open:

$14.81

24h Volume:

2.16M

Relative Volume:

1.82

Market Cap:

$1.59B

Revenue:

$83.98M

Net Income/Loss:

$-264.46M

P/E Ratio:

-5.0754

EPS:

-3.0421

Net Cash Flow:

$-263.47M

1W Performance:

+2.59%

1M Performance:

-2.22%

6M Performance:

+85.35%

1Y Performance:

+22.73%

1-Day Range:

$14.67

$16.18

1-Week Range:

$14.01

$16.18

52-Week Range:

$8.18

$22.50

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(415) 660-5320

Address

1600 SIERRA POINT PKWY, BRISBANE

Employee

357

Twitter

Next Earnings Date

2026-04-14

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	15.44	1.49B	83.98M	-264.46M	-263.47M	-3.0421
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-24-25	Resumed	Truist	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Mar-17-25	Initiated	Leerink Partners	Market Perform
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

Mar 25, 2026

Nurix Therapeutics (NASDAQ:NRIX) Trading Up 10.9%Time to Buy? - MarketBeat

Mar 25, 2026

Winners Losers: Is Nurix Therapeutics Inc a stock for growth or value investors2026 Key Highlights & Trade Opportunity Analysis - baoquankhu1.vn

Mar 25, 2026

Retail Trends: Is Nurix Therapeutics Inc forming a bullish divergence2026 Snapshot & Technical Confirmation Trade Alerts - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Nurix Therapeutics (NASDAQ:NRIX) Given Buy Rating at HC Wainwright - MarketBeat

Mar 24, 2026

NRIX Stock: HC Wainwright & Co. Reiterates Buy Rating with $32 T - GuruFocus

Mar 24, 2026

Mar 23, 2026

Nurix Therapeutics announces presentations showcasing depth of research pipeline and scientific leadership at the American Association for Cancer Research (AACR) annual meeting - marketscreener.com

Mar 23, 2026

Nurix Therapeutics Announces Presentations Showcasing Depth Of Research Pipeline And Scientific Leadership At The American Association For Cancer Research (AACR) Annual Meeting - TradingView

Mar 23, 2026

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - Bitget

Mar 23, 2026

Nurix Therapeutics plans oral presentation on multiple degrader programs at San Diego conference - Traders Union

Mar 23, 2026

Cancer meeting to feature 5 Nurix studies, including brain tumor data - Stock Titan

Mar 23, 2026

Mar 20, 2026

Why (NRIX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Mar 20, 2026

Mar 18, 2026

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - AOL.com

Mar 18, 2026

Nurix Therapeutics hits 80-plus relative strength rating benchmark - MSN

Mar 18, 2026

Investment Recap: Is Nurix Therapeutics Inc undervalued by DCF analysisGap Up & Low Drawdown Trading Techniques - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Stocks to watch: Nurix Therapeutics sees relative strength rating jump to 83 - MSN

Mar 17, 2026

Cinctive Capital Management LP Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat

Mar 17, 2026

Short Squeeze: Can Nurix Therapeutics Inc grow without external fundingWeekly Stock Summary & Community Verified Trade Signals - baoquankhu1.vn

Mar 17, 2026

Mar 15, 2026